发明授权
- 专利标题： Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
-
申请号： US15568683申请日： 2016-04-22
-
公开(公告)号： US12128069B2公开(公告)日： 2024-10-29
- 发明人: Steven M. Albelda
- 申请人： Novartis AG , The Trustees of the University of Pennsylvania
- 申请人地址： CH PA Basel
- 专利权人： The Trustees of the University of Pennsylvania,Novartis AG
- 当前专利权人： The Trustees of the University of Pennsylvania,Novartis AG
- 当前专利权人地址： US PA Philadelphia; CH Basel
- 代理机构： Saul Ewing LLP
- 代理商 Kathryn Doyle
- 国际申请： PCT/US2016/028986 2016.04.22
- 国际公布： WO2016/172583A 2016.10.27
- 进入国家日期： 2017-10-23
- 主分类号： A61K35/17
- IPC分类号： A61K35/17 ; A61K9/00 ; A61K38/17 ; A61K39/00 ; A61K39/395 ; C07K14/47 ; C07K14/705 ; C07K14/725 ; C07K16/32 ; C12N5/0783 ; C12N15/85 ; A61K45/06 ; C12N7/00
摘要：
The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
公开/授权文献
信息查询
IPC分类:
